Researchers are engineering microbes to deliver therapeutics specifically to tumors, maximizing the treatments’ efficacy while minimizing side effects.

Autonomous, living microrobots that seek and destroy cancer are not as futuristic as one might imagine, thanks to a fusion of robotics and synthetic biology.

Researchers could one day use the method to deliver antibiotics to topical wounds infected by hard-to-treat masses of bacteria.

DNA-responsive polymer gels used for releasing drugs, encapsulating cells, and much more now have greater adaptability thanks to the Cas12a nuclease.

The US Food and Drug Administration halts a study by Solid Biosciences after a patient experiences severe side effects following treatment.

A device implanted into mice can modulate brain circuit activity over long periods of time.

A microneedle delivers liquid medicines through tiny, fang-like points.

An injectable biomaterial calls cancer drugs to tumor sites in mice.

Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.

The artificially motorized cells may one day help fight cancers in the female reproductive tract.

To treat neurological disease, researchers develop techniques to bypass or trick the guardian of the central nervous system.

The blood-brain barrier is a collection of specialized cells and proteins that control the movement of molecules from the blood to the central nervous system.

Mice receiving the treatment produced their own monoclonal antibodies and survived infection with the life-threatening pathogen Pseudomonas aeruginosa.

The mini machines treated infection somewhat better than antibiotics plus the typical proton pump inhibitor medication. 

Scientists designed autonomous nanovesicles capable of following glucose concentration gradients, even through the blood brain barrier in rats.

Researchers are developing potent ways to fuel and control the movement of micromotor devices.

A braided structure and some adhesive hydrogel make therapeutic microRNAs both stable and sticky.

Drug-delivering nanoparticles designed to glow when their target cells die can report on the effectiveness of cancer therapies within just a few hours of treatment, a mouse study shows.

Reengineered protein-shuttling machinery can be used to inject a particular protein into mammalian cells, according to a proof-of-principle study.